The deployment of antibodies as antiviral agents has progressed through a number of stages over the years, corresponding to increasing levels of potency of the reagent administered. Passive immunotherapy began with immune serum over a century ago, then progressed to polyclonal antibodies, then mAbs and now into highly potent human mAbs called as super-antibodies. Super-antibodies […]
Synthetic genes and genetic programs rely on host central dogma process i.e. replication, transcription and translation for propagation and expression. Synthetic biologists therefore write genetic programs with the host organism in mind and accept both the rigidities and regulatory complexities associated with host central dogma systems. This dependency poses two challenges; Transfer of developed genetic
Transcriptional similarity has been used to differentiate and categorize cells within a tissue, it also gives insights about functions of a cell. Similarly, we use single cell data to identify cell-type-specific markers and then label and map these cell types back in the intact tissue. Conventional ‘bulk’ methods of RNA sequencing (RNA-seq) process hundreds of
Treatment with an artificial, nontoxic prion protein (PrP) could substantially delay or even prevent the development of prion disease, according to a new study (Claudio Soto and colleagues) in a hamster model of prion disease. Researchers found that synthetic prions — dubbed ‘anti-prions’ — competed with pathogenic PrP to protect the animals against the disease.
Hallmarks of ALT are heterogeneity of telomere lengths, circular telomeric DNA, and the association between telomeres and the promyelocytic leukemia (PML) protein. This protein was first discovered as the product of the PML gene, which fuses with the RARα gene in the t(15;17) chromosomal translocation. This chromosomal abnormality causes the human acute promyelocytic leukemia (APL),